145 related articles for article (PubMed ID: 2631519)
21. Treatment program and comparison between anticoagulants and platelet aggregation inhibitors after transient ischemic attack.
Burén A; Ygge J
Stroke; 1981; 12(5):578-80. PubMed ID: 7303042
[TBL] [Abstract][Full Text] [Related]
22. [Pharma-clinics. The drug of the month. Dipyridamole-acetylsalicylic acid combination (Aggrenox)].
Scheen AJ
Rev Med Liege; 2000 Oct; 55(10):957-9. PubMed ID: 11244807
[TBL] [Abstract][Full Text] [Related]
23. European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
Forbes CD
Int J Clin Pract; 1997 Jun; 51(4):205-8. PubMed ID: 9287258
[TBL] [Abstract][Full Text] [Related]
24. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial.
Mok CK; Boey J; Wang R; Chan TK; Cheung KL; Lee PK; Chow J; Ng RP; Tse TF
Circulation; 1985 Nov; 72(5):1059-63. PubMed ID: 3899404
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Kinsella JA; Tobin WO; Cox D; Coughlan T; Collins R; O'Neill D; Murphy RP; McCabe DJ
J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):e84-92. PubMed ID: 22981273
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials.
Li X; Zhou G; Zhou X; Zhou S
J Neurol Sci; 2013 Sep; 332(1-2):92-6. PubMed ID: 23871093
[TBL] [Abstract][Full Text] [Related]
27. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Hacke W
Cerebrovasc Dis; 2002; 13 Suppl 1():22-6. PubMed ID: 11803184
[TBL] [Abstract][Full Text] [Related]
28. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Diener HC; Sacco R; Yusuf S; ;
Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
[TBL] [Abstract][Full Text] [Related]
29. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Jamieson DG; Parekh A; Ezekowitz MD
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
[TBL] [Abstract][Full Text] [Related]
30. Prevention of ischaemic stroke--antiplatelets.
McCabe DJ; Brown MM
Br Med Bull; 2000; 56(2):510-25. PubMed ID: 11092100
[TBL] [Abstract][Full Text] [Related]
31. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis.
Verro P; Gorelick PB; Nguyen D
Stroke; 2008 Apr; 39(4):1358-63. PubMed ID: 18323511
[TBL] [Abstract][Full Text] [Related]
32. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke.
Thijs V; Lemmens R; Fieuws S
Eur Heart J; 2008 May; 29(9):1086-92. PubMed ID: 18349026
[TBL] [Abstract][Full Text] [Related]
33. Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study.
Forbes CD
Thromb Res; 1998 Sep; 92(1 Suppl 1):S1-6. PubMed ID: 9781830
[TBL] [Abstract][Full Text] [Related]
34. One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel.
Burton TM; Lacey M; Liu F; Yu Y; Monsalvo ML; Lang K; Sander S
J Med Econ; 2012; 15(6):1217-25. PubMed ID: 22857539
[TBL] [Abstract][Full Text] [Related]
35. [Antithrombotic treatment as primary and secondary prevention of stroke].
Chukanova EI; Chukanova AS; Nadareyshvili GG; Gulieva MS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10):85-88. PubMed ID: 28635860
[TBL] [Abstract][Full Text] [Related]
36. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
37. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin.
Algra A; de Schryver EL; van Gijn J; Kappelle LJ; Koudstaal PJ
Cochrane Database Syst Rev; 2001; (4):CD001342. PubMed ID: 11687110
[TBL] [Abstract][Full Text] [Related]
38. Pentoxifylline for prevention of transient ischaemic attacks.
Gawel MJ; Steiner TJ; Rose FC
Lancet; 1981 Jun; 1(8232):1266. PubMed ID: 6112592
[No Abstract] [Full Text] [Related]
39. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.
; Halkes PH; van Gijn J; Kappelle LJ; Koudstaal PJ; Algra A
Lancet Neurol; 2007 Feb; 6(2):115-24. PubMed ID: 17239798
[TBL] [Abstract][Full Text] [Related]
40. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Kirshner HS
Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
